Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

The American journal of surgical pathology - 1 Apr 2015

Kleinschmidt-DeMasters Bette K, Aisner Dara L, Foreman Nicholas K

Abstract excerpt

Epithelioid glioblastomas (E-GBMs) manifest BRAF V600E mutation in up to 50% of cases, compared with a small percentage of ordinary GBMs, suggesting that they are best considered variants rather than a different pattern of GBM. Availability of a targeted therapy, vemurafenib, may make testing BRAF status important for treatment. It is unclear whether BRAF VE1 immunohistochemistry (IHC) can substitute for Sanger...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma
Share to In Situ Hybridization, Fluorescence

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Indoles

Share to Patient Selection

Share to Precision Medicine

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 25581727
DOI: 10.1097/PAS.0000000000000363
PMCID: PMC4617316

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.PMID 25581727Read ↗

Cells with ganglionic differentiation frequently stain for VE1 antibody: a potential pitfall.Semantic proximity Read ↗

Epithelioid GBMs show a high percentage of BRAF V600E mutation.Semantic proximity Read ↗

Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature.Semantic proximity Read ↗

BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.Semantic proximity Read ↗

The Significance of BRAF Mutation in the Epithelioid Glioblastoma Subtype: A Systematic Literature Review and a Case Report with a Unique Intraventricular Topography.Semantic proximity Read ↗

BRAF-V600E immunohistochemistry in a large series of glial and glial-neuronal tumors.Semantic proximity Read ↗

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells.Semantic proximity Read ↗

Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.Semantic proximity Read ↗

[Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study].Semantic proximity Read ↗

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.Semantic proximity Read ↗

The Immunoreactivity Patterns of BRAF VE1 and its Diagnostic Value in Brain TumorsSemantic proximity Read ↗

Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.